200 related articles for article (PubMed ID: 37291203)
21. Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D-NKG2DL dependent manner.
Fernández L; Valentín J; Zalacain M; Leung W; Patiño-García A; Pérez-Martínez A
Cancer Lett; 2015 Nov; 368(1):54-63. PubMed ID: 26276724
[TBL] [Abstract][Full Text] [Related]
22. Potential of human γδ T cells for immunotherapy of osteosarcoma.
Li Z
Mol Biol Rep; 2013 Jan; 40(1):427-37. PubMed ID: 23065272
[TBL] [Abstract][Full Text] [Related]
23. Chimeric Antigen Receptor-modified T cells targeting EphA2 for the immunotherapy of paediatric bone tumours.
Hsu K; Middlemiss S; Saletta F; Gottschalk S; McCowage GB; Kramer B
Cancer Gene Ther; 2021 Apr; 28(3-4):321-334. PubMed ID: 32873870
[TBL] [Abstract][Full Text] [Related]
24. Glycan Structures in Osteosarcoma as Targets for Lectin-Based Chimeric Antigen Receptor Immunotherapy.
Prasse N; Wessolowski C; Müller I; Cornils K; Franke AK
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791381
[TBL] [Abstract][Full Text] [Related]
25. Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors.
Stock S; Benmebarek MR; Kluever AK; Darowski D; Jost C; Stubenrauch KG; Benz J; Freimoser-Grundschober A; Moessner E; Umana P; Subklewe M; Endres S; Klein C; Kobold S
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35902133
[TBL] [Abstract][Full Text] [Related]
26. [Specific cytotoxicity of a novel HER2-based chimeric antigen receptor modified T lymphocytes against HER2-positive tumor cells].
Tang HJ; Liu YQ; Bian XC; Feng HL; Gu B; Sun H; Zuo CX; Zhou FY; Liu J
Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):714-720. PubMed ID: 29050075
[No Abstract] [Full Text] [Related]
27. Modulation of immunosuppressive cells and noncoding RNAs as immunotherapy in osteosarcoma.
Xia Y; Wang D; Piao Y; Chen M; Wang D; Jiang Z; Liu B
Front Immunol; 2022; 13():1025532. PubMed ID: 36457998
[TBL] [Abstract][Full Text] [Related]
28. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients.
Marofi F; Rahman HS; Al-Obaidi ZMJ; Jalil AT; Abdelbasset WK; Suksatan W; Dorofeev AE; Shomali N; Chartrand MS; Pathak Y; Hassanzadeh A; Baradaran B; Ahmadi M; Saeedi H; Tahmasebi S; Jarahian M
Stem Cell Res Ther; 2021 Aug; 12(1):465. PubMed ID: 34412685
[TBL] [Abstract][Full Text] [Related]
29. A second-generation CD38-CAR-T cell for the treatment of multiple myeloma.
Li H; Li J; Wu J; Shi Z; Gao Y; Song W; Li J; Li Z; Zhang M
Cancer Med; 2023 May; 12(9):10804-10815. PubMed ID: 37039305
[TBL] [Abstract][Full Text] [Related]
30. Surface expression of the immunotherapeutic target G
Wiebel M; Kailayangiri S; Altvater B; Meltzer J; Grobe K; Kupich S; Rossig C
Cancer Rep (Hoboken); 2021 Oct; 4(5):e1394. PubMed ID: 33811471
[TBL] [Abstract][Full Text] [Related]
31. Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia.
Trad R; Warda W; Alcazer V; Neto da Rocha M; Berceanu A; Nicod C; Haderbache R; Roussel X; Desbrosses Y; Daguindau E; Renosi F; Roumier C; Bouquet L; Biichle S; Guiot M; Seffar E; Caillot D; Depil S; Robinet E; Salma Y; Deconinck E; Deschamps M; Ferrand C
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35803613
[TBL] [Abstract][Full Text] [Related]
32. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z
Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445
[TBL] [Abstract][Full Text] [Related]
33. Construction of CAR-T cells targeting TM4SF1 and its anti-tumor capacity in ovarian cancer.
Shen Y; Liu G; Zhang Q; Tian X; Ouyang L; Zhang L
Immunol Lett; 2023 Mar; 255():1-9. PubMed ID: 36739093
[TBL] [Abstract][Full Text] [Related]
34. Generation and Functional Characterization of PLAP CAR-T Cells against Cervical Cancer Cells.
Yekehfallah V; Pahlavanneshan S; Sayadmanesh A; Momtahan Z; Ma B; Basiri M
Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139135
[TBL] [Abstract][Full Text] [Related]
35. Fourth-generation chimeric antigen receptor T cells targeting folate receptor alpha antigen expressed on breast cancer cells for adoptive T cell therapy.
Luangwattananun P; Junking M; Sujjitjoon J; Wutti-In Y; Poungvarin N; Thuwajit C; Yenchitsomanus PT
Breast Cancer Res Treat; 2021 Feb; 186(1):25-36. PubMed ID: 33389403
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy for osteosarcoma: Where do we go from here?
Wedekind MF; Wagner LM; Cripe TP
Pediatr Blood Cancer; 2018 Sep; 65(9):e27227. PubMed ID: 29923370
[TBL] [Abstract][Full Text] [Related]
37. Promise and Challenges of T Cell Immunotherapy for Osteosarcoma.
Park JA; Cheung NV
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569894
[TBL] [Abstract][Full Text] [Related]
38. Natural Killer Cell Immunotherapy for Osteosarcoma.
Tullius BP; Setty BA; Lee DA
Adv Exp Med Biol; 2020; 1257():141-154. PubMed ID: 32483737
[TBL] [Abstract][Full Text] [Related]
39. Preclinical Evaluation of Chimeric Antigen Receptor-Modified T Cells Specific to Epithelial Cell Adhesion Molecule for Treating Colorectal Cancer.
Zhang BL; Li D; Gong YL; Huang Y; Qin DY; Jiang L; Liang X; Yang X; Gou HF; Wang YS; Wei YQ; Wang W
Hum Gene Ther; 2019 Apr; 30(4):402-412. PubMed ID: 30693795
[TBL] [Abstract][Full Text] [Related]
40. PET Reporter Gene Imaging and Ganciclovir-Mediated Ablation of Chimeric Antigen Receptor T Cells in Solid Tumors.
Murty S; Labanieh L; Murty T; Gowrishankar G; Haywood T; Alam IS; Beinat C; Robinson E; Aalipour A; Klysz DD; Cochran JR; Majzner RG; Mackall CL; Gambhir SS
Cancer Res; 2020 Nov; 80(21):4731-4740. PubMed ID: 32958548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]